Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 5, 2016, Pages 451-463

  Gardiner, Bradley J ^a   Golan, Yoav ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotic resistance; carbapenem resistant Enterobacteriaceae; Ceftazidime avibactam; Gram negative infection; lactamase; lactamase inhibitor

Indexed keywords

AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAMASE; CEFTAZIDIME; IMIPENEM; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL INFECTION; ABDOMINAL PAIN; ACINETOBACTER; ANAEROBE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BACKACHE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG CONTROL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROBACTERIACEAE; ENZYME INHIBITION; HEADACHE; HOSPITALIZATION; HUMAN; HYPERTENSION; IN VITRO STUDY; INFECTION COMPLICATION; INJECTION SITE REACTION; INSOMNIA; KIDNEY DISEASE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS; SIDE EFFECT; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; INTRAABDOMINAL INFECTIONS; MULTIDRUG RESISTANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; HUMANS; INTRAABDOMINAL INFECTIONS;

EID: 84988346636     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2016.1173542     Document Type: Article

References (104)

1. B.Spellberg, R.Guidos, D.Gilbert, et al. The epidemic of antibiotic-resistant infections:a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155–164.
2. H.W.Boucher, G.H.Talbot, D.K.BenjaminJr., et al. 10 x ‘20 progress–development of new drugs active against gram-negative bacilli:an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685–1694.
3. H.W.Boucher, G.H.Talbot, J.S.Bradley, et al. Bad bugs, no drugs:no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
4. K.Coleman Diazabicyclooctanes (DBOs):a potent new class of non-beta-lactam beta-lactamase inhibitors. Curr Opin Microbiol. 2011;14(5):550–555.
5. K.Bush. The ABCD’s of beta-lactamase nomenclature. J Infect Chemother. 2013;19(4):549–559.
6. K.Bush. Proliferation and significance of clinically relevant beta-lactamases. Ann N Y Acad Sci. 2013;1277:84–90.
7. K.Bush. Carbapenemases:partners in crime. J Global Antimicrob Resist. 2013;1(1):7–16.
8. L.F.Chen, J.T.Freeman, B.Nicholson, et al. Widespread dissemination of CTX-M-15 genotype extended-spectrum-beta-lactamase-producing enterobacteriaceae among patients presenting to community hospitals in the southeastern United States. Antimicrob Agents Chemother. 2014;58(2):1200–1202.
9. R.Banerjee, J.R.Johnson. A new clone sweeps clean:the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2014;58(9):4997–5004.
10. N.K.Petty, N.L.Ben Zakour, M.Stanton-Cook, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A. 2014;111(15):5694–5699.
11. S.M.Drawz, R.A.Bonomo. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.
12. K.Bush. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46(5):483–493.
13. E.Maseda, L.Aguilar, M.-J.Gimenez, et al. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther. 2014;12(11):1311–1324.
14. H.C.Neu, P.Labthavikul. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982;21(1):11–18.
15. P.Lagace-Wiens, A.Walkty, J.A.Karlowsky. Ceftazidime-avibactam:an evidence-based review of its pharmacology and potential use in the treatment of gram-negative bacterial infections. Core Evid. 2014;9:13–25.
16. G.G.Zhanel, C.D.Lawson, H.Adam, et al. Ceftazidime-avibactam:a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013;73(2):159–177.
17. D.E.Ehmann, H.Jahic, P.L.Ross, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012;109(29):11663–11668.
18. T.Stachyra, M.C.Pechereau, J.M.Bruneau, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother. 2010;54(12):5132–5138.
19. A.Bonnefoy, C.Dupuis-Hamelin, V.Steier, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother. 2004;54(2):410–417.
20. T.Stachyra, P.Levasseur, M.C.Pechereau, et al. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother. 2009;64(2):326–329.
21. S.Das, J.Li, J.Armstrong, et al. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect. 2015;3(5):e00172.
22. H.Merdjan, M.Rangaraju, A.Tarral. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers:results of two randomized, placebo-controlled studies. Clin Drug Investig. 2015;35(5):307–317.
23. N.Tominaga, T.Edeki, J.Li, et al. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. J Infect Chemother. 2015;21(8):551–558.
24. J.Li, M.Learoyd, F.Qiu, et al. A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime-avibactam in healthy Chinese subjects. Clin Drug Investig. 2016;36(2):119–126.
25. Avycaz (Ceftazidime-Avibactam). Package insert. Cincinnati, OH:Forest Pharmaceuticals; 2015.• Package insert.
26. T.R.Keepers, M.Gomez, C.Celeri, et al. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against beta-lactamase-producing enterobacteriaceae and pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014;58(9):5297–5305.
27. S.T.Housman, J.L.Crandon, W.W.Nichols, et al. Efficacies of ceftazidime-avibactam and ceftazidime against pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother. 2014;58(3):1365–1371.
28. M.L.Grayson, S.M.Crowe, J.S.McCarthy, et al. Kucers’ the use of antibiotics sixth edition, a clinical review of antibacterial, antifungal and antiviral drugs. Hoboken:CRC Press; 2010.
29. A.M.Queenan, K.Bush. Carbapenemases:the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440–458.
30. W.A.Craig. Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10.
31. P.Bhagunde, K.T.Chang, E.B.Hirsch, et al. Novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother. 2012;56(5):2237–2240.
32. K.Coleman, P.Levasseur, A.M.Girard, et al. Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014;58(6):3366–3372.
33. J.Berkhout, M.J.Melchers, A.C.Van Mil, et al. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays. Antimicrob Agents Chemother. 2015;59(2):1138–1144.
34. J.Dallow, L.G.Otterson, M.D.Huband, et al. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. Int J Antimicrob Agents. 2014;44(6):552–556.
35. CLSI. Performance standards for antimicrobial susceptibility testing. Wayne (PA):Clinical and Laboratory Standards Institute; 2014.
36. EUCAST. European committee on antimicrobial susceptibility testing:clinical breakpoints. EUCAST. European Society of Clinical Microbiology and Infectious Diseases; 2016 Available at www.eucast.org
37. R.N.Jones, N.M.Holliday, K.M.Krause. Validation of sensititre dry-form broth microdilution panels for susceptibility testing of ceftazidime-avibactam, a broad-spectrum-beta-lactamase inhibitor combination. Antimicrob Agents Chemother. 2015;59(8):5036–5039.
38. D.Halimi, G.Stone, F.Bulcher, et al. Comparative evaluation of ceftazidime-avibactam MIC testing with Etest CZA256 and CLSI broth microdilution methods. San Diego (CA):ICAAC; 2015.
39. H.S.Sader, M.Castanheira, R.K.Flamm, et al. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother. 2014;58(3):1684–1692.• Large US-based microbiologic survey demonstrating in vitro activity of CTZ–AVI against a wide variety of Gram-negative organisms.
40. R.K.Flamm, D.J.Farrell, H.S.Sader, et al. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother. 2014;69(6):1589–1598.
41. M.Castanheira, S.E.Farrell, K.M.Krause, et al. Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. Antimicrob Agents Chemother. 2014;58(2):833–838.
42. M.Castanheira, J.C.Mills, S.E.Costello, et al. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother. 2015;59(6):3509–3517.
43. R.K.Flamm, H.S.Sader, D.J.Farrell, et al. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis. 2014;80(3):233–238.
44. H.S.Sader, M.Castanheira, D.J.Farrell, et al. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). Diagn Microbiol Infect Dis. 2015;83(4):389–394.
45. H.S.Sader, M.Castanheira, R.K.Flamm, et al. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents. 2015;46(1):53–59.
46. H.S.Sader, M.Castanheira, R.E.Mendes, et al. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother. 2015;59(6):3656–3659.
47. A.J.Denisuik, J.A.Karlowsky, T.Denisuik, et al. In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible gram-negative clinical isolates obtained from patients in Canadian hospitals. Antimicrob Agents Chemother. 2015;59(6):3623–3626.
48. R.K.Flamm, G.G.Stone, H.S.Sader, et al. Avibactam reverts the ceftazidime MIC90 of European gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother. 2014;26(6):333–338.
49. P.Levasseur, A.M.Girard, M.Claudon, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012;56(3):1606–1608.
50. Z.Aktas, C.Kayacan, O.Oncul. In vitro activity of avibactam (NXL104) in combination with beta-lactams against gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39(1):86–89.
51. P.R.Lagace-Wiens, F.Tailor, P.Simner, et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother. 2011;55(5):2434–2437.
52. A.Endimiani, Y.Choudhary, R.A.Bonomo. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother. 2009;53(8):3599–3601.
53. X.Wang, F.Zhang, C.Zhao, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58(3):1774–1778.
54. P.Levasseur, A.M.Girard, C.Miossec, et al. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized beta-lactamases. Antimicrob Agents Chemother. 2015;59(4):1931–1934.• Microbiologic study demonstrating restoration of activity of ceftazidime following addition of avibactam in resistant Enterobacteriaceae.
55. N.T.Mutters, S.Zimmermann, M.Kaase, et al. Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-nonsusceptible Enterobacteriaceae without carbapenemase production. Eur J Clin Microbiol Infect Dis. 2015;34(12):2429–2437.
56. C.Pitart, F.Marco, T.A.Keating, et al. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015;59(6):3059–3065.
57. D.M.Livermore, S.Mushtaq, M.Warner, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55(1):390–394.
58. A.Walkty, M.DeCorby, P.R.Lagace-Wiens, et al. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011;55(6):2992–2994.
59. S.Mushtaq, M.Warner, D.M.Livermore. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother. 2010;65(11):2376–2381.• Microbiologic study demonstrating in-vitro resistance to CTZ–AVI via non-β-lactamase mechanisms.
60. A.Yoshizumi, Y.Ishii, K.Aoki, et al. In vitro susceptibility of characterized beta-lactamase-producing gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations. J Infect Chemother. 2015;21(2):148–151.
61. D.M.Citron, K.L.Tyrrell, V.Merriam, et al. In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrob Agents Chemother. 2011;55(7):3616–3620.
62. R.K.Shields, C.J.Clancy, B.Hao, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother. 2015;59(9):5793–5797.
63. M.L.Winkler, K.M.Papp-Wallace, R.A.Bonomo. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. J Antimicrob Chemother. 2015;70(8):2279–2286.
64. M.L.Winkler, K.M.Papp-Wallace, M.A.Taracila, et al. Avibactam and inhibitor-resistant SHV beta-lactamases. Antimicrob Agents Chemother. 2015;59(7):3700–3709.
65. P.Levasseur, A.M.Girard, L.Lavallade, et al. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2014;58(11):6490–6495.
66. S.H.MacVane, J.L.Crandon, W.W.Nichols, et al. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2014;58(11):6913–6919.
67. M.Borgonovi, C.Miossec, J.Lowther. The efficacy of ceftazidime combined with NXL104, a novel beta-lactamase inhibitor, in a mouse model of kidney infections induced by beta-lactamase producing Enterobacteriaceae. Abstract P794. Clin Microbiol Infect. 2007;13(Suppl. 2):S199–200. Plus poster presented at 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 Mar 31–Apr 3; Munich.
68. A.Endimiani, K.M.Hujer, A.M.Hujer, et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(1):82–85.• In vivo animal model demonstrating efficacy of CTZ–AVI.
69. J.L.Crandon, V.J.Schuck, M.A.Banevicius, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(12):6137–6146.
70. J.S.Solomkin, J.E.Mazuski, J.S.Bradley, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children:guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–164.
71. C.Lucasti, I.Popescu, M.K.Ramesh, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults:results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68(5):1183–1192.•• Phase II clinical trial.
72. J.A.Vazquez, L.D.Gonzalez Patzan, D.Stricklin, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults:results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28(12):1921–1931.•• Phase II clinical trial.
73. R.E.Mendes, M.Castanheira, L.Gasink, et al. beta-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam:clinical efficacies analyzed against subsets of molecularly characterized isolates. Antimicrob Agents Chemother. 2015;60(3):1328–1335.
74. J.E.Mazuski, L.Gasink, J.Armstrong, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection - results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016 Mar 8. doi:10.1093/cid/ciw133. [Epub ahead of print]•• First published Phase III clinical trial.
75. Positive Phase III Results Demonstrate Efficacy Of Antibiotic Medicine AVYCAZ™ (ceftazidime-avibactam) In Complicated Urinary Tract Infections. Allergen, Inc. [cited 2016 Jan 20]. Available from:http://www.allergan.com/news/news/thomson-reuters/positive-phase-iii-results-demonstrate-efficacy-of
76. Y.Carmeli, J.Armstrong, P.J.Laud et al. Efficacy and safety of ceftazidime-avibactam and best available therapy in the treatment of ceftazidime-resistant infections - results from a Phase III study. Poster presentation, ECCMID, LBEV0061b. 2015.
77. S.Das, J.Armstrong, D.Mathews, et al. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. J Clin Pharmacol. 2014;54(3):331–340.
78. M.U.Rashid, S.Rosenborg, G.Panagiotidis, et al. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Int J Antimicrob Agents. 2015;46(1):60–65.
79. Infectious Diseases Society of America, B.Spellberg, M.Blaser, et al. Combating antimicrobial resistance:policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5):S397–428.
80. M.L.Grayson, N.Macesic, J.Trevillyan, et al. Fosfomycin for treatment of prostatitis:new tricks for old dogs. Clin Infect Dis. 2015;61(7):1141–1143.
81. B.J.Gardiner, A.A.Mahony, A.G.Ellis, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101–105.
82. D.E.Ehmann, H.Jahic, P.L.Ross, et al. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem. 2013;288(39):27960–27971.
83. J.M.Pages, S.Peslier, T.A.Keating, et al. The role of the outer membrane and porins in the susceptibility of beta-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrob Agents Chemother. 2015;60(3):1349–1359.
84. H.Xu, S.Hazra, J.S.Blanchard. NXL104 irreversibly inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry. 2012;51(22):4551–4557.
85. J.Berkhout, M.J.Melchers, A.C.Van Mil, et al. Pharmacodynamics of Ceftazidime and Avibactam in neutropenic mice with thigh- or lung-infection. Antimicrob Agents Chemother. 2015;60(1):368–375.
86. D.Curcio. Activity of a novel combination against multidrug-resistant nonfermenters:ceftazidime plus NXL104. Expert Rev Anti Infect Ther. 2011;9(2):173–176.
87. S.D.Lahiri, R.A.Giacobbe, M.R.Johnstone, et al. Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C beta-lactamase enzyme. J Antimicrob Chemother. 2014;69(11):2942–2946.
88. H.Li, M.Estabrook, G.A.Jacoby, et al. In vitro susceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015;59(3):1789–1793.
89. D.M.Livermore, S.Mushtaq, M.Warner, et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother. 2008;62(5):1053–1056.
90. K.M.Papp-Wallace, M.L.Winkler, J.A.Gatta, et al. Reclaiming the efficacy of beta-lactam-beta-lactamase inhibitor combinations:avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. Antimicrob Agents Chemother. 2014;58(8):4290–4297.
91. F.Caravaca-Fontan, S.Jimenez-Alvaro, R.Marcen-Letosa, et al. Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation. Nefrologia. 2015;35(4):412–413.
92. R.M.Humphries, S.Yang, P.Hemarajata, et al. First report of ceftazidime-avibactam resistance in a KPC-3 expressing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;59(10):6605–6607.
93. S.D.Lahiri, G.K.Walkup, J.D.Whiteaker, et al. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother. 2015;70(6):1650–1658.
94. D.M.Livermore, M.Warner, D.Jamrozy, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 Carbapenemase. Antimicrob Agents Chemother. 2015;59(9):5324–5330.
95. K.M.Papp-Wallace, M.L.Winkler, M.A.Taracila, et al. Variants of beta-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother. 2015;59(7):3710–3717.
96. G.K.Thomson, J.W.Snyder, C.L.McElheny, et al. Co-production of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae:implications for newer beta-lactam-beta-lactamase inhibitor combinations. J Clin Microbiol. 2015;54(3):791–794.
97. M.L.Winkler, K.M.Papp-Wallace, A.M.Hujer, et al. Unexpected challenges in treating multidrug-resistant gram-negative bacteria:resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015;59(2):1020–1029.
98. C.Bebrone, P.Lassaux, L.Vercheval, et al. Current challenges in antimicrobial chemotherapy:focus on ss-lactamase inhibition. Drugs. 2010;70(6):651–679.
99. K.Bush, M.J.Macielag. New beta-lactam antibiotics and beta-lactamase inhibitors. Expert Opin Ther Pat. 2010;20(10):1277–1293.
100. K.Garber. A beta-lactamase inhibitor revival provides new hope for old antibiotics. Nat Rev Drug Discov. 2015;14(7):445–447.
101. Y.Mawal, I.A.Critchley, T.A.Riccobene, et al. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Expert Rev Clin Pharmacol. 2015;8(6):691–707.
102. D.P.Nicolau. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015;24(9):1261–1273.
103. C.A.Thompson. Ceftazidime with beta-lactamase inhibitor approved for complicated infections. Am J Health Syst Pharm. 2015;72(7):511.
104. E.J.Zasowski, J.M.Rybak, M.J.Rybak. The beta-lactams strike sack:ceftazidime-avibactam. Pharmacotherapy. 2015;35(8):755–770.